Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
clinical data for ILUVIEN® (fluocinolone acetonide intravitreal
implant 0.19mg) will be featured in multiple papers and discussions
at the Annual Meeting of the American Academy of Ophthalmology,
taking place at the Moscone Center in San Francisco from October
12-15, 2019.
Five ePosters featuring long-term clinical efficacy and safety
data for ILUVIEN will be available for viewing at the conference,
with three having subsequent discussion sessions following their
initial availability.
“We are pleased to once again showcase the differentiated
benefits of ILUVIEN for the treatment of DME in several new
clinical papers and discussions at this year’s AAO conference,”
said Rick Eiswirth, CEO of Alimera. “There continues to be a high
level of interest from U.S. and international investigators to
learn more about ILUVIEN and the therapy’s ability to control the
recurrence of DME by continuously and consistently treating the
disease for up to three years. We continue to invest in generating
additional clinical data and real-world experience studies from the
more than 20,000 ILUVIEN injections to date, and plan to share
additional data at future ophthalmology conferences.”
Details for the posters and discussions are as
follows:
Poster Number: PO412Title: “Global Safety Update: Long Term IOP
Outcomes in Patients Receiving the 0.2 ug/day Fluocinolone
Acetonide (ILUVIEN) intravitreal implant”Author: Caesar Luo, Bay
Area Retina Associates Discussion Topic/Date/Time: Retina,
Vitreous; Saturday, October 12, 2019; 12:45 PM PT
Poster Number: PD27Title: “Fluocinolone acetonide (Fac)
intravitreal implant for refractory DME: 3 years and beyond”Author:
Anastasios Sepetis, University Hospital, Southampton, NHS,
UKDiscussion Topic/Date/Time: Retina, Vitreous; Sunday, October 13,
2019; 12:45 PM PT
Poster Number: PO418Title: “Switching Therapy for Refractory
DME: Twelve- and 24-Month Results with Fluocinolone Intravitreal
Implant”Author: Argyrios Chronopoulos, Universite de Geneve,
GermanyDiscussion Topic/Date/Time: Retina, Vitreous; Monday,
October 14, 2019; 12:00 PM PT
Remaining ePosters, which may be accessed during the entire
meeting, include:PO458: “Outcomes achieved with the intravitreal
0.19 mg fluocinolone acetonide implant – results from the German
perspective IDEAL registry study”Author: Ramin Khoramnia,
Universtat Heidelberg, Germany
PO472: “Timing and Treatment Considerations for Reimplantation
with 0.19-mg Fluocinolone Acetonide (ILUVIEN) implant”Author:
Matthew Manry, Eye Center of Northern Colorado
For those interested in attending or accessing the
presentations, the conference program is available at
https://www.aao.org/annual-meeting/program-highlights/program-highlights-2.
About The American Academy of Ophthalmology
The American Academy of Ophthalmology (AAO) is the world’s
largest association of eye physicians and surgeons. A global
community of 32,000 medical doctors, the AAO protects sight and
empowers lives by setting the standards for ophthalmic education
and advocating for its patients and the public. The AAO innovates
to advance the ophthalmology profession and works to ensure
delivery of the highest-quality eye care.
About ILUVIEN
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant, injected into the back of
the eye. With its CONTINUOUS MICRODOSINGTM technology, ILUVIEN is
designed to release submicrogram levels of fluocinolone acetonide,
a corticosteroid, for up to 36 months, to reduce the recurrence of
disease, enabling patients to maintain vision longer with fewer
injections. ILUVIEN is approved in the U.S., Canada, Kuwait,
Lebanon and the U.A.E to treat diabetic macular edema (DME) in
patients who have been previously treated with a course of
corticosteroids and did not have a clinically significant rise in
intraocular pressure. In 17 European countries, ILUVIEN is
indicated for the treatment of vision impairment associated with
chronic DME considered insufficiently responsive to available
therapies. In March 2019, ILUVIEN received approval in the same 17
countries under the Mutual Recognition Procedure for prevention of
relapse in recurrent non-infectious uveitis affecting the posterior
segment of the eye. The 17 European countries include the U.K.,
Germany, France, Italy, Spain, Portugal, Ireland, Austria, Belgium,
Denmark, Norway, Finland, Sweden, Poland, Czech Republic, the
Netherlands, and Luxembourg. The regulatory process is now in
the national phase in which the European member states have
finalized or are expected to finalize the label for the new
indication to meet each country’s local requirements. Timeline to
this goal varies by each country. ILUVIEN is not approved for
treatment of uveitis in the United States.
About Alimera Sciences, Inc.
Alimera, founded in June 2003, is a pharmaceutical company that
specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals for the management of
retinal diseases. Alimera is presently focused on diseases
affecting the back of the eye, or retina, because these diseases
are not well treated with current therapies and will affect
millions of people in our aging populations. For more information,
please visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, that Alimera will continue to
invest in generating additional clinical data and real-world
experience studies from the more than 20,000 ILUVIEN injections to
date, and that Alimera will plan to share additional data at future
ophthalmology conferences. Such forward-looking statements are
based on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
these expectations, and could cause actual results to differ
materially from those projected in these forward-looking
statements. Meaningful factors that could cause actual results to
differ include, but are not limited to, other factors discussed in
the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of
Alimera’s Annual Report on Form 10-K for the year ended December
31, 2018, which is on file with the Securities and Exchange
Commission and available on its website at
http://www.sec.gov.
For press
inquiries: Jules Abraham for Alimera Sciences 917-885-7378
julesa@coreir.com |
For investor inquiries: Scott Gordon for Alimera
Sciences scottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2024 to May 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From May 2023 to May 2024